Pharmaceuticals

Summit Therapeutics and Akeso share prices plummet following the FDA’s rejection

Regulatory authority refuses to approve lung cancer drug: Chinese firm falls by up to 32 per cent in Hong Kong, whilst US group drops by up to 12 per cent

 masyastadnikova - stock.adobe.com

4' min read

Translated by AI
Versione italiana

4' min read

Translated by AI
Versione italiana

Summit Therapeutics and Akeso’s research into cancer immunotherapy has hit a setback in the United States. The Food and Drug Administration (FDA) has rejected, in its current form, the application for authorisation of ivonescimab, the experimental lung cancer drug developed by the two companies. This decision had an immediate impact on the markets: during the trading session on Monday 16 November on the Hong Kong stock exchange, Akeso shares fell by as much as 32 per cent before closing down 22 per cent, whilst Summit Therapeutics shares dropped by as much as 12 per cent at the opening of trading on Wall Street.

At the heart of the US regulator’s decision lies the failure to demonstrate a tangible benefit in terms of patients’ overall survival. According to the FDA, ivonescimab did not achieve a statistically significant improvement in this outcome measure. The drug was shown to slow the progression of the disease, but this result was not considered sufficient to justify its authorisation.

Loading...

Analysts have also interpreted the rejection as a sign of weakness in the ability of Chinese biotech companies to bring innovative and competitive drugs to the international market that can rival the products of major Western pharmaceutical groups.

Akeso’s disappointment

The backlash has been particularly severe for Akeso. During a conference call with investors, Chief Executive Michelle Xia acknowledged that the trial results had not met the FDA’s requirements in terms of overall survival. However, she emphasised that the company continues to believe in the drug’s potential and regards the decision as an isolated case, rather than a blanket rejection of its research platform.

“This is the most discouraging moment in the 14 years since Akeso was founded,” said Xia, whilst pointing out, however, that the company had passed the inspections carried out by the FDA at its clinical trial centres in China and its manufacturing facilities.

The manager also raised the possibility of resorting to share buy-back programmes to counter any excessive volatility in the share price. After falling as much as 32 per cent during the trading session, Akeso shares recovered towards the end of the session, closing on the Hong Kong Stock Exchange with a 22 per cent fall. For the company, however, this was the worst intraday decline since May 2024.

For Summit, too, the US regulator’s negative assessment means a delay in its commercial prospects in the United States. According to analysts at Bernstein, the FDA’s decision will put pressure on the share price in the short term, postponing the drug’s potential market launch. Chief Executive Bob Duggan expressed his disappointment on behalf of patients and families who were awaiting new treatment options, whilst confirming the company’s intention to continue the clinical development of ivonescimab for other types of cancer. The shares on the Nasdaq are trading at their 52-week low.

The challenge to Keytruda

The issue has implications that go beyond this single regulatory dossier. Ivonescimab is, in fact, one of the most advanced candidates in the field of dual-action cancer immunotherapies. The drug works on two fronts: on the one hand, it stimulates the patient’s immune system to attack cancer cells; on the other, it targets the mechanisms that promote the formation of the blood vessels necessary for tumour growth.

The project had gained significant international attention in 2024, when Summit and Akeso announced results superior to those of Keytruda – Merck’s oncology blockbuster and the world’s best-selling anti-cancer drug – in a late-stage clinical trial conducted in China. Those results had helped to fuel international interest in Chinese pharmaceutical research, leading to a series of licensing agreements for the development of similar molecules. Ivonescimab had thus become one of the key benchmarks for assessing the Chinese biotech industry’s ability to compete on global markets.

The application for approval in the United States concerned a specific category of patients with advanced non-small cell lung cancer who had already undergone treatment targeting EGFR, a protein involved in the proliferation of cancer cells. Summit had estimated that over 14,000 US patients might be eligible each year. However, this was a complex regulatory process. The US authorities had already expressed reservations about the robustness of the clinical data submitted, and analysts at Jefferies, in a note dated 27 October, had described the chances of approval as ‘minimal’.

Loading...

AstraZeneca invests 2 billion

However, this setback does not rule out the prospect of developing the drug for other indications. Summit and Akeso are currently conducting several global Phase 3 trials to assess the efficacy of ivonescimab in additional types of cancer. These include a study directly comparing the molecule with Keytruda, with initial results expected by the end of the year. Confirming the pharmaceutical industry’s interest in the project, AstraZeneca announced in September a $2 billion investment in Summit to collaborate on the development of ivonescimab and evaluate its use in combination with other drugs from the group.

The economic potential remains significant. According to estimates by Bloomberg Intelligence, should the ongoing trials confirm the molecule’s efficacy, ivonescimab could achieve total sales of $3.8 billion by 2030. Akeso would also benefit from royalties on US sales in the low double-digit percentage range.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti